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Abstract
Background—Postoperative chemotherapy is standard following preoperative chemoradiation 
therapy (CRT) and curative resection for clinically staged II/III rectal cancer. Recent trials have 
questioned whether postoperative chemotherapy improves overall survival. We evaluated the 
comparative effectiveness of postoperative chemotherapy following CRT or radiation therapy (RT) 
with specific attention on the impact of age on postoperative chemotherapy effectiveness.
Methods—Patients treated with CRT or RT then resection of pathologically staged 0-III rectal 
cancer diagnosed from 2004-2009 were identified from the Surveillance, Epidemiology and End 
Results program-Medicare database. Propensity score weighted Cox proportional hazards models 
and Kaplan Meier methods were used to compare the effectiveness of 1) postoperative 5-
fluorouracil (5-FU) or capecitabine to no treatment and 2) postoperative oxaliplatin+5-FU/
capecitabine to 5-FU/capecitabine alone on mortality. Results were stratified by age.
Results—We identified 1,316 patients; 49% received postoperative chemotherapy, 341 (52%) 
included oxaliplatin. After weighting, postoperative 5-FU/capecitabine alone was associated with 
decreased mortality in patients aged 66-74 (adjusted hazard ratio (aHR)=0.46, 95%CI: 0.30,0.72), 
corresponding to a 5-year risk difference of -0.23, (95%CI: -0.33,-0.12). No further mortality 
reduction from adding oxaliplatin to 5-FU/capecitabine was seen in patients aged 66-74 
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(aHR=1.57, 95%CI: 0.93,2.65). No mortality reduction for 5-FU/capecitabine alone was observed 
among patients aged 75+ (aHR=1.11, 95%CI: 0.76,1.63).
Conclusions—Among patients<75 years, postoperative 5-FU/capecitabine was associated with 
reduced mortality after preoperative CRT/RT and surgical resection; however, addition of 
oxaliplatin was not associated with further mortality reduction. Decisions regarding postoperative 
chemotherapy after age 75 warrants consideration of individual patient risks and preferences, as 
benefits may be limited.
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rectal cancer; chemotherapy; aging; comparative effectiveness research
Introduction
For over 30 years the standard curative approach for stage II and III rectal cancer has 
included surgical resection, chemoradiotherapy (CRT), and 5-fluoruracil (5-FU) based 
postoperative chemotherapy. This approach is based on results of randomized controlled 
trials (RCTs) conducted in the 1980s-90s where patients treated with all three modalities had 
the lowest rates of local and distant recurrence and the longest survival.[1, 2] Rectal cancer 
treatment has since evolved. Total mesorectal excision is now standard with resultant lower 
rates of local recurrence.[3-6] CRT is administered preoperatively, providing better 
functional outcomes and possibly better local control and DFS.[7, 8] In 2004, the addition of 
oxaliplatin to 5-FU or capecitabine was shown to offer incremental survival benefit for 
patients with stage III colon cancer,[9-12] and its use was rapidly incorporated into 
treatment guidelines for rectal cancer and disseminated into routine clinical practice.[13]
While the best outcomes have been observed in patients treated with all modalities, early 
trials were not designed to test the individual contribution of each component of the 
preoperative CRT and postoperative chemotherapy platform on rectal cancer outcomes. The 
Cochrane Collaboration conducted a meta-analysis of 21 RCTs to examine whether the 
postoperative chemotherapy component in isolation reduces mortality over observation.[14] 
The meta-analysis reported a 17% reduction in the relative risk of all-cause mortality 
associated with postoperative chemotherapy; however, only a single trial, EORTC 22921, 
specifically evaluated chemotherapy following modern preoperative CRT. Now after 10 
years of follow-up, 5-FU only marginally reduced mortality compared with observation 
(hazard ratio (HR)=0.91, 95%CI: 0.77,1.09); however, fewer than half of patients in EORTC 
22921 were able to complete postoperative therapy at the planned dose and schedule.[15, 16] 
A second multi-trial analysis in which individual patient data from EORTC 22921 were 
combined with that of three additional trials of chemotherapy following preoperative 
treatment showed no benefit of postoperative chemotherapy (HR=0.97, 95%CI: 0.81,1.17).
[17]
The three recently completed randomized trials comparing postoperative 5-FU/capecitabine 
with and without oxaliplatin have done little to elucidate the role of postoperative 
oxaliplatin, as in two trials the addition of oxaliplatin resulted in an improvement in disease 
free survival (DFS) of a similar magnitude as is seen in stage III colon cancer, but the third 
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reported no DFS benefit.[18-20] Though long-term follow-up is immature, it seems unlikely 
that these results will markedly change given the close relationship between DFS and overall 
survival in colorectal cancer.[21]
While expert guidelines from the National Comprehensive Cancer Network,[22] European 
Society of Medical Oncology,[23] and the National Institute for Health and Care Excellence 
[24] continue to include the recommendation to at least consider postoperative 
chemotherapy, there is insufficient data about the effectiveness of postoperative 
chemotherapy (with our without oxaliplatin) to reduce recurrence or cancer mortality in 
preoperatively-treated patients.[25, 26] Because older adults tend to be underrepresented in 
trials,[27] there are even less data regarding the effectiveness of postoperative chemotherapy 
approaches in this population.
We evaluated the effectiveness of postoperative chemotherapy with 5-FU or capecitabine 
alone - and the incremental effectiveness of oxaliplatin - following preoperative CRT and 
surgery for rectal cancer in routine care settings in the US. With over half of all patients with 
rectal cancer diagnosed over the age of 65, [28] we also specifically evaluated the impact of 
age on the comparative effectiveness of postoperative chemotherapy approaches.
Methods
Data sources
Cancer cases were obtained from the National Cancer Institute's Surveillance, 
Epidemiology, and End Results (SEER) program which collects demographic and tumor 
data for individuals diagnosed with cancer residing within one of the 18 SEER regions.[29] 
The linkage of persons in SEER with their Medicare enrollment and claims data allows for 
the identification of cancer treatments [30, 31] and extended mortality follow-up.
Study population
We included patients diagnosed with pathologically confirmed, first primary cancer of the 
rectum/rectosigmoid junction from 2004-2009, with continuous Medicare Parts A and B fee-
for-service and no managed care enrollment for the 12-months before and 6-months 
following the cancer diagnosis date, ensuring complete claims capture and to define 
covariates and treatments. Patients with American Joint Commission on Cancer (AJCC) 6th 
Edition stage 0-III were included to ensure inclusion of patients with clinical stage II and III 
rectal cancer (for which CRT is standard) who were down staged by preoperative therapy 
because pathologic stage (e.g. ypT and ypN stage) supersedes clinical stage in SEER. 
Patients who underwent complete surgical resection within 180 days from diagnosis and 
received preoperative CRT or radiation therapy alone (RT) between the date of diagnosis and 
surgery date were included in the study.
Ascertainment of treatment
Administrative codes identified cancer-directed treatments (Appendix A) and have high 
validity for identifying specific chemotherapy agents.[30-32] Postoperative chemotherapy 
was assessed from the date of surgery through the following 122 days (4 months). Specific 
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chemotherapeutic agents administered within the 60 days of the first chemotherapy 
administration were used to define the initial postoperative chemotherapy group (i.e., 5-FU/
capecitabine alone or in combination with oxaliplatin).[30, 33-35]
Ascertainment of all-cause and cancer-specific mortality
The primary outcome of interest was all-cause mortality ascertained through December 2011 
from the Medicare enrollment database.[36] Follow-up began 122 days from the surgery 
date (i.e., the landmark). The secondary outcome of cancer-specific mortality was defined 
from the death certificate cause of death reported to SEER; however, ascertainment was 
limited through December 2009.
Ascertainment of covariates
The diagnosis year, sex, age at diagnosis, race/ethnicity, marital status, region of residence, 
county and census tract level socioeconomic data were obtained from SEER.[37] 
Comorbidity was measured using conditions from Klabunde's adaptation of the Charlson 
Comorbidity Index (CCI).[38] Hospitalization within 30 days following surgical resection 
was a proxy for surgical complications, shown to be associated with both chemotherapy 
receipt and all-cause mortality.[39] For each patient, we estimated the predicted probability 
of activities of daily living dependence (ADL-D) as a proxy for frailty using a previously 
validated model.[40]
Statistical Analysis
We evaluated the association between postoperative chemotherapy with 5-FU/capecitabine 
alone versus observation and all-cause and cancer-specific mortality. We constructed a rich 
propensity score (PS) model that estimated the probability that each patient received 
postoperative 5-FU/capecitabine alone versus observation to control for measured 
confounding.[41] This model drew upon prior work,[13] including age, sex, race/ethnicity, 
marital status, metropolitan area, the proportion of individuals living below the poverty line 
within the same census tract, pathologic stage, cancer site, receipt of preoperative CRT or 
RT, specific comorbidities, hospitalization within 30 days from surgery, and the predicted 
probability of ADL-D. To control for measured confounders, we balanced the covariates 
across treatment groups using standardized mortality ratio (SMR)-weighting, assigning a 
weight of 1 for patients treated with postoperative 5-FU/capecitabine alone and a weight of 
the propensity odds [(PS)/(1-PS)] for patients who did not receive postoperative 
chemotherapy, creating a “pseudo-population” of patients who did not receive postoperative 
chemotherapy with the same covariate distribution as that observed in patients who received 
postoperative chemotherapy with 5-FU/capecitabine alone.[42, 43] Covariate balance was 
evaluated using standardized absolute mean difference (SAMD); adequate balance was 
considered as SAMD<0.1.[44]
The same analytic approach was implemented among all patients receiving postoperative 
chemotherapy in order to evaluate the association between the addition of oxaliplatin to 
postoperative 5-FU/capecitabine alone and all-cause and cancer-specific mortality. However, 
this analysis was restricted to patients aged 66-74 years in an effort to further reduce the 
potential for residual confounding by frailty among the oldest patient subgroups (where 
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oxaliplatin treatment is least likely). We constructed a separate PS model to estimate the 
probability that each patient was treated with postoperative oxaliplatin (compared with 5-FU 
or capecitabine alone).
Cox proportional hazards models with SMR weights and robust standard errors (to account 
for the lack of independence due to weighting) were used to estimate adjusted hazard ratios 
(aHRs) and their 95% confidence intervals (CIs) for all-cause and cancer-specific mortality. 
Analyses of cancer-specific mortality accounted for non-cancer death as a competing risk.
[45] The weighted cumulative incidence of all-cause and cancer-specific mortality was 
plotted for each postoperative treatment comparison and used to calculate adjusted 3- and 5-
year risk ratios (aRRs) and risk differences (aRDs).[46] Ninety-five percent confidence 
intervals (CIs) were generated using the standard deviation of 200 bootstraps. Analyses for 
the comparison of postoperative chemotherapy versus observation were further stratified by 
age group (<75 vs.75+ years, based on clinical input), pathologic stage (0-I, II, III) and 
preoperative treatment (CRT vs. RT only). Exploratory analyses evaluated treatment effect 
heterogeneity by age on all-cause mortality in greater detail using a 5-year age-stratified 
moving window approach. All data were analyzed in SAS, version 9.3 (SAS Institute, Cary, 
NC). The institutional review board at the University of North Carolina at Chapel Hill 
determined that this research was exempt from review.
Results
Patterns of postoperative chemotherapy
In total, 1,316 patients with non-metastatic rectal cancer 66 years and older were included 
(Figure 1). Approximately half of eligible patients received postoperative chemotherapy 
following preoperative CRT and resection (n=650, 49%) and 341 (52%) of these 
chemotherapy treated patients received oxaliplatin (Table 1). Older age, lower stage, 
metropolitan residence and 30-day post-surgical hospitalization were associated with lower 
use of postoperative chemotherapy with 5-FU/capecitabine alone (versus observation), while 
comorbid peripheral vascular disease and preoperative CRT receipt were associated with 
higher use (Supplemental Table 1a). Among patients age 66-74 years who received 
postoperative chemotherapy, older age, higher census tract poverty level, lower stage and 30-
day post-surgical hospitalization were associated with lower oxaliplatin receipt 
(Supplemental Table 1b). After PS weighting, measured characteristics were well balanced 
across treatment groups (SAMD <0.1, Supplemental Tables 2a-b).
Effectiveness of postoperative 5-FU or capecitabine alone
Over a mean follow-up of 3.8 and 3.5 years for postoperative 5-FU/capecitabine groups and 
observation, respectively, all-cause mortality was significantly lower for those patients 
treated with postoperative 5-FU/capecitabine alone compared to observation (HR=0.68, 
95%CI: 0.52, 0.88, Supplemental Table 3a). This survival benefit was not substantially 
altered by control for measured confounding (aHR=0.72, 95%CI 0.55, 0.96).
The benefit of postoperative 5-FU/capecitabine over observation was restricted to patients 
aged 66-74 years (aHR=0.46, 95%CI: 0.30, 0.72, Figure 2, Supplemental Table 3a). This 
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translates to an absolute risk reduction in all-cause mortality of 14% at 3 years (aRD=-0.14, 
95%CI: -0.23, -0.04) and 23 % at 5 years (aRD=-0.23, 95%CI: -0.33, -0.12), leading to a 3- 
and 5-year number needed to treat (NNT) of 7 and 4 (Table 2), assuming a causal effect. In 
contrast, patients aged 75+ years did not appear to benefit from postoperative 5-FU/
capecitabine alone compared with observation (aHR=1.11, 95%CI: 0.76, 1.63, Figure 2, 
Supplemental Table 3a).
The substantial mortality reduction associated with postoperative 5-FU/capecitabine alone 
does not seem largely related to unmeasured confounding based on treatment selection as 
cancer-specific mortality was similarly better in the postoperative 5-FU/capecitabine treated 
patients compared to untreated patients in the entire cohort (aHR=0.81, 95%CI 0.50-1.31, 
Supplemental Table 3a) and in patients aged 66-74 (aHR=0.41, 95%CI 0.19, 0.86, Figure 2, 
Supplemental Table 3a) though not in patients over 75 (aHR=1.03, 95%CI 0.57, 1.87, Figure 
2, Supplemental Table 3a). Stratified results did not indicate effect measure modification by 
pathologic stage, although associations by preoperative treatment receipt were imprecise 
(Supplemental Figure 1).
The exploratory analysis of treatment effect heterogeneity revealed a pattern of attenuating 
aHRs with increasing age (Figure 3), with the aHR reaching 1.0 at the age midpoint of 74 
years (aHR=1.00, 95%CI: 0.59, 1.69). This analysis confirms the approximate clinical 
selection of age 75 years as a cutpoint for stratified analyses.
Comparative effectiveness of postoperative oxaliplatin versus 5-FU/
capecitabine alone—Because of the observed lack of benefit of postoperative 
chemotherapy and the small number of patients over the age of 75 treated with oxaliplatin, 
we only evaluated the comparative effectiveness of adding oxaliplatin to 5-FU/capecitabine 
alone on all-cause and cancer-specific mortality in patients aged 66-74 years. Overall, there 
were 79 deaths; 29 in the 5-FU or capecitabine alone group and 50 in the postoperative 
oxaliplatin group with a median follow-up of 4.1 and 3.6 years, respectively. Oxaliplatin was 
not associated with an improvement in all-cause mortality compared with 5-FU/capecitabine 
alone in patients aged 66-74 years (aHR=1.57, 95%CI: 0.93, 2.65, Figure 2, Supplemental 
Table 3b). This translated into a non-significant increase in absolute risk at 3 years 
(aRD=0.04, 95%CI: -0.03, 0.11, Table 3), and significant increase in the risk of death at 5 
years (aRD=0.10, 95%CI: 0.03, 0.18), leading to a 5-year number needed to treat to harm 
(NNTH)[47] of 10. The lack of observed mortality reduction and potential harm of 
oxaliplatin among patients aged 66-74 was also seen in cancer-specific mortality analyses, 
although these results were imprecise.
Discussion
Postoperative 5-FU/capecitabine alone following preoperative CRT and surgical resection 
was associated with lower all-cause and cancer-specific mortality compared with 
observation in this large cohort of Medicare beneficiaries. However, the benefits of 
postoperative chemotherapy on mortality reduction appear to be attenuated with advancing 
age, with no clear benefit observed in patients 75 years or older. We found no evidence that 
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oxaliplatin incrementally reduced mortality compared with 5-FU/capecitabine alone among 
patients aged 66-74 years old.
Multiple European trials have specifically addressed the role of postoperative chemotherapy 
versus observation following CRT for rectal cancer.[17] In the analysis of patient data from 
four of these trials, three of which used 5-FU and leucovorin and one which used oxaliplatin 
with capecitabine, there was no suggestion of benefit from postoperative chemotherapy on 
survival (HR 0.97, 95%CI 0.81-1.17) or DFS (HR 0.91, 95%CI 0.77-1.07).[17] Low 
adherence to the protocol prescribed postoperative chemotherapy (where most patients were 
randomized at diagnosis and not after surgery) is a key limitation that has prevented these 
results from changing the long accepted belief that postoperative chemotherapy improves 
outcomes in resected rectal cancer. While seemingly contradictory, our study was designed 
to specifically address the role of postoperative chemotherapy among patients treated with 
timely preoperative CRT and surgery, rather than the entire CRT and chemotherapy program 
and therefore may better represent the isolated impact of postoperative chemotherapy among 
patients able to initiate treatment following surgical resection.
Although we used SMR-weighting methods with validated, novel measures of frailty to 
address measured confounding, it is likely that our estimate of an approximately 50% 
reduction in the risk of death following postoperative 5-FU/capecitabine alone versus 
observation among patients aged 66-74 is an overestimate of the actual treatment effect. In 
observational studies estimating treatment effectiveness, a key limitation is the inability to 
directly measure a number of key prognostic factors, notably frailty, performance status, and 
pretreatment clinical staging. This is particularly problematic in the comparison of 
postoperative 5-FU/capecitabine alone to observation, as the reasons that underlie the 
decision to forgo chemotherapy (e.g. frailty) are likely also related to increased mortality, 
thus failure to adequately control for these factors would lead us to overestimate the benefit 
of postoperative chemotherapy. Our study design, however, inherently decreases the 
potential for residual confounding by frailty, as all patients had to undergo active 
preoperative CRT or RT followed by curative surgical resection (e.g. not just local excision), 
thereby excluding patients deemed ineligible for aggressive treatment based on frailty or 
comorbidity. This type of restriction strategy has been found to be effective in reducing 
residual confounding by frailty.[48, 49] Bias related to treatment selection would be likely to 
have the greatest effect on all-cause mortality, yet we also observed a substantial reduction 
in cancer-related mortality associated with 5-FU/capecitabine alone. Thus, while it is 
unlikely that we could estimate the exact magnitude of the effect of 5-FU/capecitabine 
alone, we believe the design and findings of this study support the conclusion that 
postoperative 5-FU/capecitabine alone compared with observation likely reduces mortality 
following preoperative CRT/RT and surgery in patients with rectal cancer under 75 years.
While postoperative 5-FU/capecitabine alone reduced mortality among the entire cohort, 
there was no reduction observed among patients over age 75 at diagnosis. This decreasing 
benefit of postoperative therapy with increasing age among the elderly has been reported in 
subgroup analyses of patients with colon cancer treated in clinical trials. The landmark 
pooled analysis of patient data from randomized adjuvant 5-FU trials by Sargent in 2001 
confirmed a similar benefit of 5-FU on freedom from recurrence in patients 70 years and 
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over; however while there was no statistical evidence of interaction of age and survival, the 
survival difference between treated and untreated patients diminished with increasing follow 
up, presumably due to the higher rates of death from other causes.[50] Limitations of our 
data preclude us from evaluating the effect on recurrence specifically, and the follow-up time 
for cancer-specific survival is too short to make definitive conclusions based on those 
results.
The balance of evidence from the three recently reported trials supports the benefit of 
postoperative oxaliplatin versus 5-FU/capecitabine alone on DFS.[18, 20] In the one 
negative trial, patients were randomized at diagnosis and the resultant low completion rates 
make it difficult to interpret the postoperative chemotherapy effect (only 52% of patients 
randomized to oxaliplatin and 66% of patients randomized to capecitabine completed 
planned postoperative therapy).[19] Limitations of our data did not allow us to incorporate 
therapy completion into our analyses, which could mask the potential benefits of 
postoperative oxaliplatin. However, our analysis was designed to estimate the association of 
starting oxaliplatin versus 5-FU/capecitabine alone as an initial strategy, which answers a 
clinically relevant, but different question.
If oxaliplatin likely improves DFS in patients following resection of preoperatively treated 
rectal cancer, the pattern of benefit in rectal cancer may be akin to what is seen in colon 
cancer where oxaliplatin unequivocally works in younger patients but not in older patients. 
Just as we found no mortality reduction attributable to postoperative oxaliplatin in patients 
66-74 years old, a pooled analysis of oxaliplatin in patients 70 and older with stage III colon 
cancer found oxaliplatin was associated with a slight improvement in time to recurrence over 
5-FU alone, but there was no improvement in DFS or overall survival.[51] In the pooled 
analysis in colon cancer and our evaluation of patients aged 66-74 in SEER-Medicare, there 
was a slight suggestion that the addition of oxaliplatin may actually lead to harm. Because of 
the short follow-up for cancer-specific mortality and lack of information on recurrence, it is 
premature to conclude that oxaliplatin increases mortality. The possibility for harm should, 
however,be considered when counseling older patients about the addition of oxaliplatin to 5-
FU/capecitabine alone following preoperative CRT and surgical resection of rectal cancer.
In summary, postoperative 5-FU/capecitabine alone was associated with a considerable 
reduction in mortality following preoperative CRT and surgery for non-metastatic rectal 
cancer in patients younger than 75 years compared with observation. Patients over the age of 
75 should be counseled that any potential benefit of postoperative therapy after resection is 
likely to be small and treatment decisions should consider individual risks and preferences. 
Similar to the colon cancer setting, our data do not support the addition of oxaliplatin to 
postoperative chemotherapy in older patients with resected rectal cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study population flowchart
Cohort inclusion and exclusion criteria for older individuals diagnosed with pathologically 
staged, non-metastatic rectal cancer at age 66 years or older using the Surveillance, 
Epidemiology and End Results program (SEER)-Medicare linked data from 2003-2009.
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Figure 2. Figure 2a-f. Propensity score-weighted cumulative all-cause and cancer-specific 
mortality among patients with non-metastatic rectal cancer who received postoperative 5-FU or 
capecitabine alone vs. no postoperative chemotherapy by age group (panels a-d) and 
postoperative oxaliplatin vs. postoperative 5-FU/capecitabine alone among patients age 66-74 
years (panels e-f)
In panels a-d, the blue (solid) line represents the cumulative incidence of the specific 
outcome (i.e., all-cause or cancer specific mortality) for individuals who received 
postoperative 5-FU/capecitabine alone while the red (dashed) line represents the cumulative 
incidence of the outcome for individuals who did not receive postoperative chemotherapy. In 
panels e-f, the blue (solid) line represents the cumulative incidence of the outcome for 
individuals who received postoperative oxaliplatin and the red (dashed) line represents the 
cumulative incidence of the outcome for individuals who received postoperative 5-FU/
capecitabine alone.
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Figure 3. Exploratory analysis of treatment effect heterogeneity by age at diagnosis comparing 
postoperative 5-FU/capecitabine alone versus no postoperative chemotherapy and all-cause 
mortality
The solid black line denotes the adjusted hazard ratio estimated using age-stratified 
subgroups and a one-year moving window, resulting in 25 estimates. All estimates used 5-
year age groupings (e.g., 71-75 years, age midpoint=73 years), when possible. The estimates 
for age 66 and 67 used one and three-year age groups, respectively. Estimates for ages 
beyond 90 years were not calculated, as data was sparse. The adjusted hazard ratios are 
plotted at the midpoint of each age group along with robust 95% confidence intervals 
(plotted on the log scale).
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